Raynaud disease (primary Raynaud phenomenon) is a vasospastic disorder characterized by episodic, excessive vasoconstriction of digital arteries and arterioles triggered by cold exposure or emotional stress. It manifests as triphasic color changes of the fingers and toes (pallor, cyanosis, erythema) reflecting vasospasm, deoxygenation, and reperfusion hyperemia. Primary Raynaud disease occurs without an underlying connective tissue disease and involves primarily functional vascular abnormalities. Secondary Raynaud phenomenon is associated with autoimmune conditions such as systemic sclerosis and involves both functional and structural vascular changes. The pathogenesis involves dysregulated neurovascular control, endothelial dysfunction, alpha-2C adrenoceptor-mediated vasoconstriction amplified by RhoA/ROCK signaling, and impaired nitric oxide-soluble guanylate cyclase-cGMP vasodilatory pathways.
Ask a research question about Raynaud Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Raynaud Disease
category: Complex
parents:
- Vascular Disorder
disease_term:
preferred_term: Raynaud disease
term:
id: MONDO:0008364
label: Raynaud disease
synonyms:
- Raynaud Phenomenon
- Raynaud Syndrome
- Primary Raynaud Phenomenon
description: >
Raynaud disease (primary Raynaud phenomenon) is a vasospastic disorder characterized
by episodic, excessive vasoconstriction of digital arteries and arterioles triggered
by cold exposure or emotional stress. It manifests as triphasic color changes of the
fingers and toes (pallor, cyanosis, erythema) reflecting vasospasm, deoxygenation,
and reperfusion hyperemia. Primary Raynaud disease occurs without an underlying
connective tissue disease and involves primarily functional vascular abnormalities.
Secondary Raynaud phenomenon is associated with autoimmune conditions such as
systemic sclerosis and involves both functional and structural vascular changes.
The pathogenesis involves dysregulated neurovascular control, endothelial dysfunction,
alpha-2C adrenoceptor-mediated vasoconstriction amplified by RhoA/ROCK signaling,
and impaired nitric oxide-soluble guanylate cyclase-cGMP vasodilatory pathways.
prevalence:
- population: General
percentage: 3.0
notes: Estimated prevalence 3-5% in the general population, with higher prevalence in women than men.
evidence:
- reference: PMID:25770637
reference_title: "Raynaud syndrome."
supports: SUPPORT
snippet: "The estimated prevalence in the general population is 3%-5%, with a higher prevalence in women than in men."
explanation: General population prevalence estimate from vascular surgery review.
has_subtypes:
- name: Primary Raynaud Phenomenon
description: >
Idiopathic vasospastic episodes without underlying connective tissue disease.
Primarily functional vascular abnormalities with symmetric involvement, younger
age of onset, and milder course. Digital tissue damage is uncommon.
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "In primary RP, the vascular abnormalities are primarily functional."
explanation: Distinguishes primary RP as functional versus structural in secondary RP.
- name: Secondary Raynaud Phenomenon
description: >
Raynaud phenomenon occurring in the context of an underlying disease, most commonly
systemic sclerosis, systemic lupus erythematosus, or mixed connective tissue disease.
Associated with both functional and structural vascular changes and higher risk of
digital ulceration and tissue loss.
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "in secondary RP, both functional and structural components occur in blood vessels. This explains why digital tissue damage frequently occurs in secondary RP but not primary RP."
explanation: Structural vascular changes explain complications in secondary RP.
pathophysiology:
- name: Alpha-2C Adrenoceptor Cold-Induced Vasoconstriction
description: >
Cold triggers alpha-2C adrenoceptor (ADRA2C) activation in microvascular smooth
muscle cells, mediating local cooling-induced vasoconstriction of digital arteries
and arterioles. Alpha-2C-AR is the sole mediator of cold-induced vasoconstriction
in the peripheral vasculature.
gene:
preferred_term: ADRA2C
term:
id: hgnc:283
label: ADRA2C
cell_types:
- preferred_term: Vascular Smooth Muscle Cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
biological_processes:
- preferred_term: Vasoconstriction
term:
id: GO:0042310
label: vasoconstriction
- preferred_term: Cellular Response to Cold
term:
id: GO:0070417
label: cellular response to cold
locations:
- preferred_term: Digital Artery
term:
id: UBERON:0004552
label: digital artery
downstream:
- target: RhoA/ROCK Potentiation of Vasospasm
description: Alpha-2C-AR activation is potentiated by RhoA/ROCK signaling.
evidence:
- reference: PMID:25770637
reference_title: "Raynaud syndrome."
supports: SUPPORT
snippet: "alterations in activity of the peripheral adrenoceptor have been implicated, specifically an enhanced smooth muscle contraction due to overexpression or hyperactivity of postsynaptic alpha 2 receptors"
explanation: Alpha-2 adrenoceptor hyperactivity drives the exaggerated smooth muscle contraction.
- reference: PMID:40506673
reference_title: "Cold responses and hormonal echoes: a comprehensive view of Raynaud's vascular dysfunction."
supports: SUPPORT
snippet: "estrogen plays a fundamental role in potentiating the expression and function of α2C adrenoceptor (α2C-AR), the sole mediator of local cooling-induced vasoconstriction"
explanation: Identifies alpha-2C-AR as the sole mediator of cold-induced vasospasm.
- name: RhoA/ROCK Potentiation of Vasospasm
description: >
RhoA/ROCK signaling potentiates alpha-2C adrenoceptor-mediated vasoconstriction
and reactive oxygen species generation in vascular smooth muscle cells, amplifying
the vasospastic response to cold.
biological_processes:
- preferred_term: Vascular Smooth Muscle Contraction
term:
id: GO:0014829
label: vascular associated smooth muscle contraction
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "Raynaud's phenomenon (RP) is a condition characterized by episodic, excessive vasoconstriction in the fingers and toes, triggered by cold or stress."
explanation: Establishes the core vasospastic mechanism that RhoA/ROCK potentiates.
- name: Estrogen Potentiation of Alpha-2C-AR
description: >
Estrogen potentiates alpha-2C adrenoceptor expression and function, contributing
to the significantly higher incidence of Raynaud phenomenon in premenopausal
females compared to age-matched males.
evidence:
- reference: PMID:40506673
reference_title: "Cold responses and hormonal echoes: a comprehensive view of Raynaud's vascular dysfunction."
supports: SUPPORT
snippet: "Raynaud's phenomenon incidence is significantly higher in premenopausal females compared to age-matched males, highlighting a role of the female hormone, estrogen, in Raynaud's phenomenon pathogenesis."
explanation: Estrogen potentiates alpha-2C-AR, explaining sex-based differences in RP incidence.
- name: Endothelial Dysfunction
description: >
Impaired endothelium-dependent vasodilation with reduced nitric oxide (NO) and
prostacyclin bioavailability and increased production of endothelin-1 (ET-1).
The imbalance between vasoconstrictors and vasodilators favors persistent
vasoconstriction, platelet activation, and intimal proliferation. In secondary RP
associated with systemic sclerosis, endothelial damage leads to defective
angiogenesis, endothelial-to-mesenchymal transition, and progressive capillary loss.
cell_types:
- preferred_term: Endothelial Cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: Vasodilation
term:
id: GO:0042311
label: vasodilation
- preferred_term: Nitric Oxide Biosynthesis
term:
id: GO:0006809
label: nitric oxide biosynthetic process
evidence:
- reference: DOI:10.3390/ijms241814385
supports: SUPPORT
snippet: "Endothelial damage and activation occur early, possibly triggered by various infectious agents and autoantibodies. Endothelial dysfunction, along with defects in endothelial progenitor cells, leads to defective angiogenesis and vasculogenesis."
explanation: Endothelial dysfunction is an early event driving vascular pathology.
- reference: DOI:10.3390/biomedicines12061331
supports: SUPPORT
snippet: "once damaged, endothelial cells can be dysfunctionally activated, thus becoming unable to undergo angiogenesis and promoting perivascular inflammation. They can also undergo apoptosis, transdifferentiate into profibrotic myofibroblasts"
explanation: Describes mechanisms of endothelial dysfunction including EndoMT and failed angiogenesis in SSc-associated RP.
- name: Sympathetic Nervous System Dysregulation
description: >
Increased sympathetic adrenergic control of digital resistance vessels contributes
to exaggerated cold-induced vasoconstriction. The pathogenesis involves a complex
interaction between the vascular wall, nerves, hormones, and humoral factors
disrupting the balance between vasoconstriction and vasodilation.
cell_types:
- preferred_term: Sympathetic Neuron
term:
id: CL:0011103
label: sympathetic neuron
biological_processes:
- preferred_term: Temperature Homeostasis
term:
id: GO:0001659
label: temperature homeostasis
locations:
- preferred_term: Manual Digit
term:
id: UBERON:0002389
label: manual digit
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "The pathogenesis of RP involves a complex interaction between the vascular wall, nerves, hormones, and humoral factors, disrupting the balance between vasoconstriction and vasodilation."
explanation: Neurovascular dysregulation as a central mechanism.
- name: Intravascular and Platelet Abnormalities
description: >
Platelet activation and release of thromboxane A2 and serotonin contribute to
vasospasm. Altered coagulation and fibrinolysis pathways and increased blood
viscosity further impair microvascular flow during episodes. Gene ontology analysis
identifies enrichment in negative regulation of fibrinolysis and complement/coagulation
cascades among RP-associated genes.
cell_types:
- preferred_term: Platelet
term:
id: CL:0000233
label: platelet
biological_processes:
- preferred_term: Platelet Activation
term:
id: GO:0030168
label: platelet activation
evidence:
- reference: DOI:10.1515/tjb-2023-0197
supports: SUPPORT
snippet: "A significant enrichment by gene ontology enrichment analysis was detected in a subset of genes involved in biological processes including cellular response to luteinizing hormone stimulus, negative regulation of fibrinolysis, negative regulation of smooth muscle cell apoptotic process, plasminogen activation"
explanation: GO analysis of RP-associated genes shows enrichment in coagulation/fibrinolysis pathways relevant to intravascular abnormalities.
- reference: DOI:10.1515/tjb-2023-0197
supports: SUPPORT
snippet: "Through the use of KEGG pathways, we were able to identify many molecular processes that contribute to RP, including the AGE-RAGE signaling pathway in diabetic complications, complement and coagulation cascades, fluid shear stress, atherosclerosis."
explanation: KEGG analysis confirms complement/coagulation cascade involvement in RP.
- name: Oxidative Stress and Ischemia-Reperfusion Injury
description: >
Recurrent vasospastic episodes cause ischemia-reperfusion injury with generation
of reactive oxygen species (ROS) and endothelial damage. ROS-dependent signaling
also regulates alpha-2C-AR expression and translocation in vascular smooth muscle
cells, creating a feed-forward loop of vascular dysfunction.
biological_processes:
- preferred_term: Response to Oxidative Stress
term:
id: GO:0006979
label: response to oxidative stress
evidence:
- reference: PMID:24418302
reference_title: "Raynaud's phenomenon: from molecular pathogenesis to therapy."
supports: SUPPORT
snippet: "recent advances in our understanding of the pathophysiology have highlighted novel potential therapeutic targets"
explanation: Prete et al. review discusses pathogenic mechanisms including oxidative stress in RP pathophysiology.
phenotypes:
- category: Vascular
name: Raynaud Phenomenon
frequency: OBLIGATE
diagnostic: true
description: >
Episodic vasospasm of digital arteries triggered by cold or stress, producing the
characteristic triphasic color change: pallor (ischemia), cyanosis (deoxygenation),
and erythema (reperfusion). This is the defining clinical feature.
phenotype_term:
preferred_term: Raynaud phenomenon
term:
id: HP:0030880
label: Raynaud phenomenon
evidence:
- reference: PMID:25770637
reference_title: "Raynaud syndrome."
supports: SUPPORT
snippet: "Raynaud syndrome (RS) was first described by the French physician Maurice Raynaud in 1862 with the characteristic tricolor change featuring pallor (ischemic phase), cyanosis (deoxygenation phase), and erythema (reperfusion phase) induced by cold or stress."
explanation: Classic triphasic color change as the hallmark clinical feature.
- reference: PMID:24418302
reference_title: "Raynaud's phenomenon: from molecular pathogenesis to therapy."
supports: SUPPORT
snippet: "Raynaud's phenomenon (RP) is a well defined clinical syndrome characterized by recurrent episodes of digital vasospasm triggered by exposure to physical/chemical or emotional stress."
explanation: Defines RP as a clinical syndrome of recurrent digital vasospasm.
- category: Vascular
name: Acrocyanosis
frequency: VERY_FREQUENT
description: >
Blue discoloration of affected digits following the ischemic phase, reflecting
deoxygenation of static venous blood. Represents the second phase of the triphasic
color change.
phenotype_term:
preferred_term: Acrocyanosis
term:
id: HP:0001063
label: Acrocyanosis
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "Pallor indicates reduced blood flow due to oxygen deprivation, while erythema appears as reperfusion."
explanation: Describes the color change phases including cyanosis between pallor and erythema.
- category: Pain
name: Digital Pain and Paresthesia
frequency: VERY_FREQUENT
description: >
Pain, numbness, and tingling in affected digits during and after vasospastic episodes.
Ischemic pain from vasospasm and neurogenic sensitization are major symptomatic burdens.
phenotype_term:
preferred_term: Paresthesia
term:
id: HP:0003401
label: Paresthesia
evidence:
- reference: PMID:29237099
reference_title: "Calcium channel blockers for primary and secondary Raynaud's phenomenon."
supports: SUPPORT
snippet: "Raynaud's phenomenon is a vasospastic disease characterized by digital pallor, cyanosis, and extremity pain."
explanation: Pain is a core characteristic feature of Raynaud phenomenon.
- category: Dermatological
name: Digital Ulceration
frequency: VERY_RARE
description: >
Ischemic ulcers at fingertips resulting from recurrent severe ischemia, endothelial
damage, and failed angiogenesis. Occurs predominantly in secondary Raynaud phenomenon
associated with systemic sclerosis. Rare in primary Raynaud disease.
phenotype_term:
preferred_term: Digital ulcer
term:
id: HP:0031917
label: Digital ulcer
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "digital tissue damage frequently occurs in secondary RP but not primary RP"
explanation: Digital ulceration is characteristic of secondary rather than primary RP.
- reference: PMID:24418302
reference_title: "Raynaud's phenomenon: from molecular pathogenesis to therapy."
supports: SUPPORT
snippet: "sRP can evolve and be complicated by acral digital ulcers and gangrene, which may require surgical treatment"
explanation: Secondary RP can progress to digital ulcers and gangrene.
- category: Vascular
name: Digital Ischemia
frequency: FREQUENT
description: >
Reduced blood flow to digits during vasospastic episodes causing tissue hypoxia.
In severe or secondary disease, sustained ischemia may lead to tissue necrosis.
phenotype_term:
preferred_term: Digital ischemia
term:
id: HP:0033402
label: Digital ischemia
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "Pallor indicates reduced blood flow due to oxygen deprivation"
explanation: Digital pallor reflects ischemia from vasospasm-induced blood flow reduction.
environmental:
- name: Cold Exposure
description: >
Cold ambient temperature or direct contact with cold objects is the primary trigger
for vasospastic episodes. Cold triggers alpha-2C adrenoceptor-mediated vasoconstriction
in digital smooth muscle cells.
exposure_term:
preferred_term: exposure to decreased temperature
term:
id: ECTO:0001057
label: exposure to decreased temperature
evidence:
- reference: PMID:40506673
reference_title: "Cold responses and hormonal echoes: a comprehensive view of Raynaud's vascular dysfunction."
supports: SUPPORT
snippet: "Raynaud's phenomenon is a peripheral vascular disorder characterized by exaggerated vasoconstrictive response to certain stimuli, most typically cold exposure and emotional stress."
explanation: Cold exposure is the primary trigger for RP attacks.
- reference: PMID:40506673
reference_title: "Cold responses and hormonal echoes: a comprehensive view of Raynaud's vascular dysfunction."
supports: SUPPORT
snippet: "estrogen plays a fundamental role in potentiating the expression and function of α2C adrenoceptor (α2C-AR), the sole mediator of local cooling-induced vasoconstriction"
explanation: Cold exposure activates alpha-2C-AR-mediated vasoconstriction.
- name: Emotional Stress
description: >
Psychological stress and emotional disturbance can trigger vasospastic episodes
through sympathetic nervous system activation, independent of cold exposure.
evidence:
- reference: PMID:24418302
reference_title: "Raynaud's phenomenon: from molecular pathogenesis to therapy."
supports: SUPPORT
snippet: "recurrent episodes of digital vasospasm triggered by exposure to physical/chemical or emotional stress"
explanation: Emotional stress is a recognized trigger alongside physical stimuli.
treatments:
- name: Calcium Channel Blockers
description: >
Dihydropyridine calcium channel blockers (e.g., nifedipine, amlodipine) are
first-line pharmacotherapy. They reduce frequency and severity of vasospastic
attacks by inhibiting calcium influx into vascular smooth muscle cells.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: nifedipine
term:
id: CHEBI:7565
label: nifedipine
- preferred_term: amlodipine
term:
id: CHEBI:2668
label: amlodipine
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "Dihydropyridine calcium channel blockers (CCBs), such as nifedipine, are commonly used for vasodilation."
explanation: CCBs are established first-line pharmacotherapy for RP.
- reference: PMID:29237099
reference_title: "Calcium channel blockers for primary and secondary Raynaud's phenomenon."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "CCBs (especially the dihydropyridine class) may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon."
explanation: Cochrane systematic review of 38 RCTs demonstrating CCBs reduce attack frequency and severity.
- name: Cold Avoidance and Protective Measures
description: >
Behavioral modification including wearing warm gloves, avoiding cold exposure,
and using hand warmers. First-line non-pharmacological management for all patients
with Raynaud phenomenon.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: PMID:25770637
reference_title: "Raynaud syndrome."
supports: SUPPORT
snippet: "Most patients with RS can be managed conservatively, with avoidance of cold exposure or hand warming."
explanation: Conservative management with cold avoidance is first-line for most patients.
- name: Phosphodiesterase-5 Inhibitors
description: >
Sildenafil and tadalafil improve digital blood flow by inhibiting PDE5, increasing
cGMP levels, and enhancing nitric oxide-mediated vasodilation. Used as second-line
therapy for refractory cases or when CCBs are insufficient.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: sildenafil
term:
id: CHEBI:9139
label: sildenafil
- preferred_term: tadalafil
term:
id: CHEBI:71940
label: tadalafil
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "Phosphodiesterase-5 inhibitors and prostaglandin analogs are alternative options for patients who do not respond to CCBs or have ischemic tissue damage."
explanation: PDE5 inhibitors are second-line options for refractory RP.
- reference: PMID:28281457
reference_title: "Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Sildenafil improved digital blood flow and RP symptoms in SSc patients after 8 weeks of treatment, and might be a good therapeutic option for secondary RP."
explanation: RCT demonstrating sildenafil improves microvascular blood flow in SSc-associated RP.
- name: Prostacyclin Analogues
description: >
Intravenous iloprost is used for severe Raynaud phenomenon with digital ischemia
or ulceration. Provides potent vasodilation and antiplatelet effects.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: iloprost
term:
id: CHEBI:63916
label: iloprost
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "Phosphodiesterase-5 inhibitors and prostaglandin analogs are alternative options for patients who do not respond to CCBs or have ischemic tissue damage."
explanation: Prostacyclin analogs are alternative options for severe/refractory RP.
- name: Endothelin Receptor Antagonists
description: >
Bosentan blocks endothelin-1 receptor signaling and has shown effectiveness in
treating and preventing digital ulcers, especially in patients with systemic
sclerosis-associated Raynaud phenomenon with multiple ulcers.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: bosentan
term:
id: CHEBI:51450
label: bosentan
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: SUPPORT
snippet: "Bosentan, an endothelin-1 receptor antagonist, has shown effectiveness in treating and preventing digital ulcers, especially in patients with multiple ulcers."
explanation: Bosentan is effective for digital ulcer prevention in SSc-associated RP.
- name: Sympathectomy
description: >
Surgical sympathectomy can be used for severe, refractory Raynaud phenomenon
to reduce sympathetic vasoconstriction. Long-term effectiveness is uncertain.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:39040029
reference_title: "Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment."
supports: PARTIAL
snippet: "sympathectomy surgery can be used to control RP symptoms. However, botulinum toxin injections require repeated administration, and sympathectomy's long-term effectiveness is uncertain."
explanation: Sympathectomy is an option for severe cases but has uncertain long-term efficacy.
notes: >
Raynaud phenomenon was first described by the French physician Maurice Raynaud in
1862. The condition affects approximately 3-5% of the general population with a
higher prevalence in women. Primary RP is a benign condition with functional vascular
abnormalities, while secondary RP (associated with systemic sclerosis, SLE, and
other connective tissue diseases) involves structural vascular changes and risk of
digital ulcers. Diagnosis is primarily clinical, with nailfold capillaroscopy serving
as the gold standard for distinguishing primary from secondary RP. Genetic and
hormonal factors (particularly estrogen) are likely contributors, and GWAS-identified
genes are enriched in vascular damage and fibrosis pathways.
datasets:
updated_date: '2026-04-22T20:53:03Z'
Pathophysiology description Raynaud disease is characterized by episodic, exaggerated vasoconstriction of the digital microvasculature triggered by cold or emotional stress, producing the classic triphasic color change (pallor → cyanosis → rubor) and ischemic pain. A contemporary model integrates dysregulated neurovascular control and endothelial dysfunction with humoral mediators and redox injury: cold/stress triggers α-adrenergic vasoconstriction in digital arterioles, which is amplified by microvascular smooth muscle cell (VSMC) α2C‑adrenoceptor signaling and RhoA/ROCK pathways; concomitantly, impaired endothelial nitric oxide (NO)–soluble guanylate cyclase (sGC)–cGMP signaling and increased endothelin‑1 (ET‑1) drive a persistent vasoconstrictive, pro‑proliferative state. Recurrent vasospasm provokes ischemia–reperfusion injury, reactive oxygen species (ROS) generation, and endothelial damage. In secondary Raynaud associated with systemic sclerosis (SSc), defective angiogenesis, endothelial-to-mesenchymal transition (EndoMT), and microvascular rarefaction underlie progression to digital ulcers and tissue loss. “Primary” RP is largely functional (thermoregulatory arteriovenous anastomosis dysfunction), whereas “secondary” RP shows structural microangiopathy at nailfold capillaries that correlates with severity and complications. Management targets these mechanisms with calcium-channel blockers (first‑line), PDE5 inhibitors, prostacyclin analogs, endothelin receptor antagonists, focal botulinum toxin, and experimental ROCK inhibition. (ture2024raynaud’sphenomenona pages 1-2, romano2024recentinsightsinto pages 2-4, patnaik2023endothelialdysfunctionin pages 7-8)
Direct supporting statements - “Raynaud’s phenomenon … is episodic excessive vasoconstriction precipitated by cold or stress … [with] multifactorial pathogenesis” (review; Vascular Specialist International; Jul 23, 2024; https://doi.org/10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 1-2) - In SSc, “defective angiogenesis … usually precedes the onset of tissue fibrosis … [with] endothelial cells releasing higher levels of endothelin-1 (ET-1) and [showing] decreased nitric oxide,” promoting vasospasm and occlusive microangiopathy (Biomedicines; Jun 2024; https://doi.org/10.3390/biomedicines12061331). (romano2024recentinsightsinto pages 2-4) - RhoA/ROCK signaling and α2C‑adrenoceptors are central to cold‑induced vasoconstriction in arteriolar VSMCs; ROS and stress kinases regulate α2C expression and translocation (Inflammopharmacology; Jun 2025; https://doi.org/10.1007/s10787-025-01792-0). (fardoun2025coldresponsesand pages 10-11)
1) Core Pathophysiology - Primary mechanisms - Dysautonomia/adrenergic: Exaggerated sympathetic vasoconstriction in digital resistance vessels; cold‑triggered α2C‑adrenoceptor activation in VSMCs mediates local cooling–induced vasoconstriction and is potentiated by RhoA/ROCK and ROS signaling. (ture2024raynaud’sphenomenona pages 1-2, fardoun2025coldresponsesand pages 10-11) - Endothelial dysfunction: Reduced NO and prostacyclin with increased ET‑1 from activated/damaged endothelium; imbalance favors vasoconstriction, platelet activation, and intimal proliferation. (romano2024recentinsightsinto pages 2-4, patnaik2023endothelialdysfunctionin pages 7-8) - NO–sGC–cGMP impairment: Diminished eNOS (NOS3) bioactivity and sGC signaling reduce cGMP‑mediated VSMC relaxation, lowering vasodilatory reserve. (oztan2024determinationofmolecular pages 7-8, patnaik2023endothelialdysfunctionin pages 7-8) - Endothelin pathway: ET‑1 overproduction and altered ETA/ETB receptor signaling sustain vasoconstriction and vascular remodeling; endothelin antagonism improves SSc digital ulcer outcomes. (romano2024recentinsightsinto pages 2-4) - RhoA/ROCK: ROCK enhances VSMC contractility, α2C‑AR trafficking, and cold vasoconstriction; a target for pharmacologic inhibition. (ture2024raynaud’sphenomenona pages 1-2) - Oxidative stress/ischemia–reperfusion: Recurrent vasospasm causes ROS bursts and endothelial injury, exacerbating vasodilator deficits and promoting inflammation. (romano2024recentinsightsinto pages 2-4) - Impaired angiogenesis/EndoMT (secondary RP/SSc): EC apoptosis, EndoMT, senescence, and pro‑thrombotic activation drive capillary rarefaction and fibrosis. (romano2024recentinsightsinto pages 2-4)
Adrenergic α2C‑AR signaling; RhoA/ROCK; NO–sGC–cGMP; endothelin signaling; oxidative stress and inflammatory activation; EndoMT and angiogenesis failure. (ture2024raynaud’sphenomenona pages 1-2, romano2024recentinsightsinto pages 2-4, fardoun2025coldresponsesand pages 10-11, patnaik2023endothelialdysfunctionin pages 7-8, oztan2024determinationofmolecular pages 7-8)
Affected cellular processes
2) Key Molecular Players - Genes/Proteins (HGNC) - NOS3 (eNOS): Endothelial NO synthase; reduced activity → impaired vasodilation. (Int J Mol Sci; Sep 2023; https://doi.org/10.3390/ijms241814385). (patnaik2023endothelialdysfunctionin pages 7-8) - GUCY1A1/GUCY1B1 (sGC): NO receptor in VSMC/endothelium; reduced function limits cGMP. (Turk J Biochem; Jun 2024; https://doi.org/10.1515/tjb-2023-0197). (oztan2024determinationofmolecular pages 7-8) - EDN1 (ET‑1), EDNRA/EDNRB: Vasoconstrictor axis elevated in SSc; drives vasospasm and vascular remodeling. (Biomedicines; Jun 2024; https://doi.org/10.3390/biomedicines12061331). (romano2024recentinsightsinto pages 2-4) - ADRA2C (α2C‑adrenoceptor): Mediates local cold‑induced vasoconstriction in cutaneous VSMCs. (Inflammopharmacology; Jun 2025; https://doi.org/10.1007/s10787-025-01792-0). (fardoun2025coldresponsesand pages 10-11) - RHOA/ROCK1/ROCK2: Smooth muscle contractility and α2C‑AR trafficking; therapeutic target. (Vascular Specialist International; Jul 2024; https://doi.org/10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 1-2) - CALCA/CGRP: Neuropeptide vasodilator and nociceptive modulator in digital microcirculation. (Vascular Specialist International; Jul 2024; https://doi.org/10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 12-14) - TRPA1/TRPM8: Cold‑sensing channels implicated in neurovascular responses to cold. (Inflammopharmacology; Jun 2025; https://doi.org/10.1007/s10787-025-01792-0). (fardoun2025coldresponsesand pages 14-15) - HIF1A: Hypoxia signaling during recurrent ischemia; links to fibrotic/angiogenic programs. (Biomedicines; Jun 2024; https://doi.org/10.3390/biomedicines12061331). (romano2024recentinsightsinto pages 2-4) - PDE5A: cGMP hydrolysis in VSMC; inhibition improves perfusion. (Inflammopharmacology; Jun 2025; https://doi.org/10.1007/s10787-025-01792-0). (fardoun2025coldresponsesand pages 10-11)
ROCK inhibitors (e.g., fasudil): experimental anti‑vasospasm strategy. (Vascular Specialist International; 2024; https://doi.org/10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 1-2)
Cell types (CL)
Immune cells: autoimmunity/inflammation propagate endothelial activation and fibrosis in SSc. (Int J Mol Sci; 2023; https://doi.org/10.3390/ijms241814385). (patnaik2023endothelialdysfunctionin pages 7-8)
Anatomical locations (UBERON)
3) Biological Processes (GO annotation perspective) - Vasodilation/vasoconstriction regulation via NO–sGC–cGMP and endothelin pathways; smooth muscle contraction (RhoA/ROCK); cellular response to cold/adrenergic stimulus (α2C‑AR); response to oxidative stress/ischemia–reperfusion; angiogenesis and EndoMT; platelet activation/adhesion in injured microvessels. (romano2024recentinsightsinto pages 2-4, fardoun2025coldresponsesand pages 10-11, patnaik2023endothelialdysfunctionin pages 7-8, oztan2024determinationofmolecular pages 7-8)
4) Cellular Components - Key locales include endothelial plasma membrane (eNOS/ET‑1), caveolae and cytoskeleton (α2C‑AR trafficking; ROCK targets), VSMC contractile apparatus, and extracellular space (ET‑1, CGRP, prostacyclin). sGC resides in cytosol; cGMP signaling interfaces with membrane ion channels and contractile machinery. (romano2024recentinsightsinto pages 2-4, fardoun2025coldresponsesand pages 10-11, patnaik2023endothelialdysfunctionin pages 7-8)
5) Disease Progression - Sequence of events 1) Trigger: cold or emotional stress activates sympathetic outflow and local cold sensors. 2) Vasospasm: α2C‑AR– and ROCK‑mediated constriction in digital VSMCs, potentiated by low NO/high ET‑1. 3) Ischemia–reperfusion injury: recurrent attacks generate ROS and endothelial injury. 4) Endothelial dysfunction/maladaptation: reduced NO/PGI2, increased ET‑1; in SSc, EC apoptosis, EndoMT, capillary loss and pro‑thrombotic changes. 5) Clinical complications: sustained microangiopathy leads to digital ulcers and tissue loss, especially in SSc. (ture2024raynaud’sphenomenona pages 1-2, romano2024recentinsightsinto pages 2-4, patnaik2023endothelialdysfunctionin pages 7-8)
6) Phenotypic Manifestations (HPO mapping) - Triphasic color change, ischemic pain/paresthesias, cold intolerance; in severe/secondary disease, digital ischemia and ulcers. Nailfold capillaroscopy abnormalities correlate with severity and systemic complications in SSc. (ture2024raynaud’sphenomenona pages 1-2, romano2024recentinsightsinto pages 2-4)
7) Biomarkers and recent data - Endothelial injury/activation markers: increased von Willebrand factor (vWF) and thrombomodulin; alterations in coagulation/fibrinolysis pathway components reported in RP datasets. (Turk J Biochem; 2024; https://doi.org/10.1515/tjb-2023-0197). (oztan2024determinationofmolecular pages 7-8) - Neurovascular mediator: CGRP is implicated in vasodilatory and nociceptive pathways in the digital microcirculation. (Vascular Specialist International; 2024; https://doi.org/10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 12-14) - Therapeutic response biomarker in SSc‑RP context: reductions in circulating hypoxia/inflammation‑linked mediators after iloprost infusion suggest modulation of microvascular injury biology. (Clinical and Experimental Medicine; May 2024; https://doi.org/10.1007/s10238-024-01374-4). (ture2024raynaud’sphenomenona pages 1-2)
8) Therapeutic mechanisms and real‑world implementations (2023–2024 emphasis) - First‑line: dihydropyridine calcium‑channel blockers (e.g., nifedipine) reduce attack frequency and severity via VSMC Ca2+ influx inhibition. (Vascular Specialist International; 2024; https://doi.org/10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 1-2) - PDE5 inhibitors (e.g., sildenafil, tadalafil): increase cGMP to counter impaired NO–sGC signaling; used for refractory RP, including SSc‑RP. (Inflammopharmacology; 2025; https://doi.org/10.1007/s10787-025-01792-0). (fardoun2025coldresponsesand pages 10-11) - Prostacyclin analogs (iloprost): intravenous courses for severe ischemia/digital ulcers, improving perfusion and inflammatory/hypoxia biomarkers. (Vascular Specialist International; 2024; https://doi.org/10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 1-2) - Endothelin receptor antagonists (e.g., bosentan): reduce new digital ulcers in SSc by blocking ET‑1 signaling. (Biomedicines; 2024; https://doi.org/10.3390/biomedicines12061331). (romano2024recentinsightsinto pages 2-4) - Botulinum toxin: local injections for refractory digital ischemia/pain; proposed to reduce neurogenic vasoconstriction and nociceptive mediators; evidence mixed; requires repeat dosing. (Vascular Specialist International; 2024; https://doi.org/10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 12-14) - ROCK inhibition (e.g., fasudil): mechanistically targets RhoA/ROCK‑mediated vasospasm; in clinical development for vasospastic disorders. (Vascular Specialist International; 2024; https://doi.org/10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 1-2)
Expert opinions and analysis Recent authoritative reviews emphasize that Raynaud’s is not a single‑pathway disorder; effective care combines lifestyle/thermal strategies with mechanism‑directed pharmacology. Endothelial dysfunction is prominent in secondary RP and predicts complications; thus, therapies that restore NO bioavailability or block ET‑1 are particularly relevant in SSc‑associated disease, whereas targeting α‑adrenergic/ROCK pathways addresses cold‑triggered vasospasm in primary RP. Persistent ischemia–reperfusion and microvascular injury explain why ulcer prevention in SSc requires more than simple vasodilation and may benefit from endothelin blockade and prostacyclin therapy. (ture2024raynaud’sphenomenona pages 1-2, romano2024recentinsightsinto pages 2-4, patnaik2023endothelialdysfunctionin pages 7-8)
Relevant statistics and study data (selected 2023–2024) - Mechanism‑informed management: reviews concur on first‑line CCBs, with PDE5 inhibitors and prostacyclin analogs for refractory/severe cases; endothelin antagonists reduce digital ulcer burden in SSc‑RP (summarized across 2024 review). (ture2024raynaud’sphenomenona pages 1-2) - Biomarkers: multiple endothelial injury markers (e.g., vWF, thrombomodulin) and coagulation pathway changes have been reported in RP cohorts/analyses (2024). (oztan2024determinationofmolecular pages 7-8) - Therapeutic biomarker modulation: in SSc cohorts, iloprost courses reduced circulating mediators linked to hypoxia/inflammation, consistent with improved microvascular function (2024). (ture2024raynaud’sphenomenona pages 1-2)
Gene/protein annotations with ontology terms (examples) - NOS3 (HGNC:7876): endothelial nitric‑oxide synthase; GO:0030168 (platelet activation—negative regulation via NO), GO:0001525 (angiogenesis—modulation via NO), GO:0005886 (plasma membrane); evidence: eNOS deficiency/dysfunction in SSc microvasculopathy (Int J Mol Sci 2023; DOI: 10.3390/ijms241814385). (patnaik2023endothelialdysfunctionin pages 7-8) - GUCY1A1/GUCY1B1 (HGNC:4514/4521): soluble guanylate cyclase subunits; GO:0006182 (cGMP biosynthetic process), GO:0005829 (cytosol); evidence of pathway implication by gene set analyses in RP (Turk J Biochem 2024; DOI: 10.1515/tjb-2023-0197). (oztan2024determinationofmolecular pages 7-8) - EDN1; EDNRA/EDNRB (HGNC:3176/3185/3186): endothelin ligand/receptors; GO:0002021 (endothelin receptor signaling pathway), GO:0005887 (integral component of plasma membrane); evidence of elevated ET‑1 and receptor involvement in SSc vasculopathy (Biomedicines 2024; DOI: 10.3390/biomedicines12061331). (romano2024recentinsightsinto pages 2-4) - ADRA2C (HGNC:282): α2C‑adrenoceptor; GO:0004935 (adrenergic receptor activity), GO:0005886 (plasma membrane); mechanistic role in cold‑induced vasoconstriction (Inflammopharmacology 2025; DOI: 10.1007/s10787-025-01792-0). (fardoun2025coldresponsesand pages 10-11) - ROCK1/ROCK2 (HGNC:10251/10252): Rho‑kinases; GO:0006940 (regulation of smooth muscle contraction), GO:0005829 (cytosol); vasospasm mediator/target (Vascular Specialist International 2024; DOI: 10.5758/vsi.240047). (ture2024raynaud’sphenomenona pages 1-2)
Phenotype associations (HPO terms, examples) - Raynaud phenomenon (HPO:0001025), Pallor of digits (HPO:0000980), Cyanosis (HPO:0000961), Erythema (HPO:0011000), Digital ulcer (HPO:0030809), Pain in limb (HPO:0030831); supported by clinical descriptions and SSc ulcer data. (ture2024raynaud’sphenomenona pages 1-2, romano2024recentinsightsinto pages 2-4)
Cell type involvement (CL terms, examples) - Endothelial cell (CL:0000115); Vascular smooth muscle cell (CL:0000359); Sympathetic neuron/peripheral nerve (CL:0000108); Leukocyte (CL:0000738). (ture2024raynaud’sphenomenona pages 1-2, romano2024recentinsightsinto pages 2-4, fardoun2025coldresponsesand pages 10-11, patnaik2023endothelialdysfunctionin pages 7-8)
Anatomical locations (UBERON terms, examples) - Digital artery/arteriole (UBERON:0004199/0001981); Nailfold (UBERON:0034915); Nipple (UBERON:0001467). (ture2024raynaud’sphenomenona pages 1-2, fardoun2025coldresponsesand pages 14-15)
Chemical entities (ChEBI examples) - Nifedipine (CHEBI:7492), Sildenafil (CHEBI:9139), Iloprost (CHEBI:6087), Bosentan (CHEBI:51236), Botulinum neurotoxin (CHEBI:132540), Fasudil (CHEBI:5013). (ture2024raynaud’sphenomenona pages 1-2, romano2024recentinsightsinto pages 2-4, fardoun2025coldresponsesand pages 10-11, ture2024raynaud’sphenomenona pages 12-14)
Evidence items with identifiers - Ture HY et al. Raynaud’s phenomenon: a current update on pathogenesis, diagnostic workup, and treatment. Vascular Specialist International. Published Jul 23, 2024. DOI: 10.5758/vsi.240047; URL: https://doi.org/10.5758/vsi.240047. (ture2024raynaud’sphenomenona pages 1-2) - Romano E et al. Recent insights into cellular and molecular mechanisms of defective angiogenesis in systemic sclerosis. Biomedicines. Published Jun 2024. DOI: 10.3390/biomedicines12061331; URL: https://doi.org/10.3390/biomedicines12061331. (romano2024recentinsightsinto pages 2-4) - Patnaik E et al. Endothelial Dysfunction in Systemic Sclerosis. International Journal of Molecular Sciences. Published Sep 2023. DOI: 10.3390/ijms241814385; URL: https://doi.org/10.3390/ijms241814385. (patnaik2023endothelialdysfunctionin pages 7-8) - Fardoun M et al. Cold responses and hormonal echoes: a comprehensive view of Raynaud’s vascular dysfunction. Inflammopharmacology. Published Jun 2025. DOI: 10.1007/s10787-025-01792-0; URL: https://doi.org/10.1007/s10787-025-01792-0. (fardoun2025coldresponsesand pages 14-15, fardoun2025coldresponsesand pages 10-11, fardoun2025coldresponsesand pages 12-13) - Öztan G. Determination of molecular pathways and gene ontology of genes associated with Raynaud’s phenomenon. Turkish Journal of Biochemistry. Published Jun 2024. DOI: 10.1515/tjb-2023-0197; URL: https://doi.org/10.1515/tjb-2023-0197. (oztan2024determinationofmolecular pages 7-8)
Structured artifact for knowledge‑base curation | Category | Entity (ontology) | Mechanistic role / description | Evidence (journal, year, DOI/URL) | Context | |---|---|---|---|---| | Gene / Protein | NOS3 (HGNC: eNOS) | Endothelial NO synthase; reduced NO production → impaired vasodilation, contributes to vasospasm and microvascular dysfunction | International Journal of Molecular Sciences, 2023, https://doi.org/10.3390/ijms241814385 (patnaik2023endothelialdysfunctionin pages 7-8) | SSc-associated RP, endothelial dysfunction | | Gene / Protein | GUCY1A1 / GUCY1B1 (HGNC: sGC subunits) | Soluble guanylate cyclase: NO receptor linking NO → cGMP; dysfunction reduces vasodilatory signaling | Turkish Journal of Biochemistry, 2024, https://doi.org/10.1515/tjb-2023-0197 (oztan2024determinationofmolecular pages 7-8) | NO–sGC–cGMP pathway impairment (primary & secondary RP) | | Gene / Protein | EDN1 (ET-1) / EDNRA / EDNRB | Endothelin-1 and receptors: potent vasoconstrictor; upregulated in SSc → sustained vasoconstriction, proliferation, fibrosis | Biomedicines, 2024, https://doi.org/10.3390/biomedicines12061331 (romano2024recentinsightsinto pages 2-4) | Prominent in SSc-associated RP and digital ischemia | | Gene / Protein | ADRA2C (α2C-AR) | Microvascular smooth muscle α2C-adrenoceptor mediates cold-induced vasoconstriction (transcriptional upregulation/translocation under cold, ROS/Rho signals) | Inflammopharmacology, 2025, https://doi.org/10.1007/s10787-025-01792-0 (fardoun2025coldresponsesand pages 14-15) | Thermoregulatory/dysautonomic axis in primary RP and risk modulation in SSc | | Gene / Protein | RHOA / ROCK1 / ROCK2 | RhoA/ROCK signaling promotes SMC contraction, cytoskeletal translocation of α2C-AR and vasospasm; therapeutic target (ROCK inhibitors) | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Vasospasm mediator (primary & secondary RP) | | Gene / Protein | CALCA / CGRP | Neuropeptide vasodilator (CGRP) — modulates neurogenic vasodilation and pain signaling in digital microcirculation | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 12-14) | Neurovascular modulation of symptoms and ischemic pain | | Gene / Protein | TRPA1 / TRPM8 (cold sensors) | Cutaneous cold receptors linking afferent neuronal cold sensing to local vascular responses and reflex vasoconstriction/vasodilation | Inflammopharmacology, 2025, https://doi.org/10.1007/s10787-025-01792-0 (fardoun2025coldresponsesand pages 14-15) | Cold-triggered reflexes in primary RP | | Gene / Protein | HIF1A | Hypoxia-inducible factor mediating responses to ischemia; drives angiogenic/ fibrotic signaling in repeated ischemia–reperfusion injury | Biomedicines, 2024, https://doi.org/10.3390/biomedicines12061331 (romano2024recentinsightsinto pages 2-4) | Tissue hypoxia, maladaptive repair in SSc-associated RP | | Gene / Protein | PDE5A | cGMP phosphodiesterase; inhibition increases cGMP → vasodilation (mechanism for sildenafil/tadalafil benefit) | Inflammopharmacology, 2025, https://doi.org/10.1007/s10787-025-01792-0 (fardoun2025coldresponsesand pages 10-11) | Therapeutic mechanism used in primary & secondary RP | | Pathway / Process | NO–sGC–cGMP signaling (GO: vasodilation) | Endothelial-derived NO → sGC activation → cGMP-mediated SMC relaxation; downregulated in RP → diminished vasodilatory reserve | Turkish Journal of Biochemistry, 2024, https://doi.org/10.1515/tjb-2023-0197 (oztan2024determinationofmolecular pages 7-8) | Central vasodilatory pathway (primary & SSc-associated RP) | | Pathway / Process | Endothelin signaling (GO: vasoconstriction / cell proliferation) | ET-1 overproduction → ETA/ETB signaling causes vasoconstriction, SMC proliferation, contributes to digital ulcers | Biomedicines, 2024, https://doi.org/10.3390/biomedicines12061331 (romano2024recentinsightsinto pages 2-4) | Key driver in SSc vasculopathy and severe RP | | Pathway / Process | α2C-AR signaling (GO: adrenergic receptor activity) | Cold-induced α2C-AR transcription/translocation in microvascular SMCs amplifies vasoconstrictive response | Inflammopharmacology, 2025, https://doi.org/10.1007/s10787-025-01792-0 (fardoun2025coldresponsesand pages 14-15) | Thermoregulatory vasospasm axis (primary RP emphasis) | | Pathway / Process | RhoA/ROCK pathway (GO: smooth muscle contraction) | ROCK-mediated cytoskeletal changes increase SMC tone and potentiate vasospasm; ROCK inhibitors under investigation | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Targetable mediator of vasospasm | | Pathway / Process | Oxidative stress & ischemia–reperfusion injury | Recurrent vasospasm → ischemia–reperfusion → ROS generation → endothelial damage, inflammation, impaired vasodilator production | Biomedicines, 2024, https://doi.org/10.3390/biomedicines12061331 (romano2024recentinsightsinto pages 2-4) | Mechanism linking episodic attacks to progressive microvascular damage (SSc) | | Pathway / Process | EndoMT & defective angiogenesis | Endothelial-to-mesenchymal transition, EC apoptosis and senescence → failed angiogenesis, capillary rarefaction, fibrosis | Biomedicines, 2024, https://doi.org/10.3390/biomedicines12061331 (romano2024recentinsightsinto pages 2-4) | Central to SSc-associated progressive vasculopathy | | Cell type | Endothelial cells (CL: EC) | Primary site of injury: reduced NO/PGI2, increased ET-1, adhesion molecule upregulation, EndoMT → microvascular loss | Biomedicines, 2024, https://doi.org/10.3390/biomedicines12061331 (romano2024recentinsightsinto pages 2-4) | SSc-associated microvascular pathology and RP initiation | | Cell type | Vascular smooth muscle cells (CL: VSMC) | SMC α2C-AR-mediated constriction, RhoA/ROCK-driven contractility and ROS-driven translocation → vasospasm | Inflammopharmacology, 2025, https://doi.org/10.1007/s10787-025-01792-0 (fardoun2025coldresponsesand pages 14-15) | Effector cell causing digital vasospasm | | Cell type | Sympathetic / perivascular nerves (CL: peripheral nerve) | Adrenergic reflexes and cold-afferent signaling regulate α-adrenergic vasoconstriction; dysautonomia contributes to exaggerated response | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Neural contribution to primary RP | | Cell type | Immune cells (CL: leukocytes) | Autoimmunity, cytokines and autoantibodies (e.g., anti-GPCRs) drive endothelial activation, inflammation and fibrosis in SSc | International Journal of Molecular Sciences, 2023, https://doi.org/10.3390/ijms241814385 (patnaik2023endothelialdysfunctionin pages 7-8) | Links RP to systemic autoimmune disease (SSc) | | Anatomy / Site | Digital microvasculature (UBERON: finger microvessels) | Target of cold/stress-triggered vasospasm → triphasic color changes, ischemia and possible ulceration | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Primary clinical site of RP events | | Anatomy / Site | Nailfold capillaries (UBERON: nailfold) | Capillaroscopy reveals early/active/late patterns; capillary loss and morphological changes reflect microangiopathy (SSc) | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Diagnostic staging and prognostic marker in SSc-associated RP | | Anatomy / Site | Nipple (UBERON: nipple) | Reported site of Raynaud phenomenon in lactating women; similar vasospastic mechanisms lead to pain and functional impact | Inflammopharmacology, 2025, https://doi.org/10.1007/s10787-025-01792-0 (fardoun2025coldresponsesand pages 14-15) | Clinical manifestation outside digits | | Drug / Chemical | Nifedipine (CHEBI) | Dihydropyridine CCB: reduces SMC Ca2+ influx → lowers frequency/severity of vasospasm; first-line for primary RP | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Standard therapy for symptomatic control | | Drug / Chemical | Sildenafil / PDE5 inhibitors (CHEBI) | Inhibit PDE5 → ↑cGMP → vasodilation, improved digital perfusion in refractory cases | Inflammopharmacology, 2025, https://doi.org/10.1007/s10787-025-01792-0 (fardoun2025coldresponsesand pages 10-11) | Second-line / adjunct therapy (primary & secondary RP) | | Drug / Chemical | Iloprost (prostacyclin analog) | Vasodilator and anti-platelet effects; randomized data show benefit in SSc-associated RP and digital ischemia | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Treatment for severe/ischemic secondary RP | | Drug / Chemical | Bosentan (endothelin receptor antagonist) | Blocks ET-1 receptors → reduces digital ulcers in SSc by countering endothelin-driven vasoconstriction | Biomedicines, 2024, https://doi.org/10.3390/biomedicines12061331 (romano2024recentinsightsinto pages 2-4) | Ulcer prevention in SSc-associated RP | | Drug / Chemical | Botulinum neurotoxin | Proposed to reduce neurogenic vasoconstriction and nociceptive signaling (mixed clinical results) | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 12-14) | Local therapy for refractory digital ischemia | | Drug / Chemical | Fasudil (ROCK inhibitor) | Inhibits ROCK → reduces SMC contractility and may limit vasospasm (clinical development for vasospastic disorders) | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Emerging targeted therapy (ROCK axis) | | Biomarker | von Willebrand factor (vWF) | Marker of endothelial activation/damage; elevated in vascular injury and associated with RP severity | Turkish Journal of Biochemistry, 2024, https://doi.org/10.1515/tjb-2023-0197 (oztan2024determinationofmolecular pages 7-8) | Indicates endothelial injury in RP and SSc | | Biomarker | Thrombomodulin | Circulating marker of endothelial dysfunction and microvascular injury | Turkish Journal of Biochemistry, 2024, https://doi.org/10.1515/tjb-2023-0197 (oztan2024determinationofmolecular pages 7-8) | Correlates with vascular severity in RP contexts | | Biomarker | CGRP | Neurogenic vasodilator peptide; serum/tissue changes reflect neurovascular involvement and pain signaling | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 12-14) | Neurovascular biomarker for symptom biology | | Biomarker | Copeptin | Surrogate of vasopressin; elevated in microcirculation alterations and correlates with Raynaud condition score in SSc cohorts | International Journal of Molecular Sciences, 2023, https://doi.org/10.3390/ijms241814385 (patnaik2023endothelialdysfunctionin pages 7-8) | Candidate marker for microvascular dysfunction in SSc | | Phenotype / HPO | Triphasic color change (pallor→cyanosis→rubor) (HPO) | Clinical signature of vasospasm followed by ischemia and reperfusion-mediated hyperemia | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Hallmark diagnostic phenotype | | Phenotype / HPO | Digital pain / paresthesia | Ischemic pain from vasospasm and neurogenic sensitization; parallels neuropeptide and nociceptive signaling | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 12-14) | Major symptomatic burden | | Phenotype / HPO | Digital ulcers / tissue loss | Result of recurrent severe ischemia, endothelial damage and failed angiogenesis (more common in SSc) | Biomedicines, 2024, https://doi.org/10.3390/biomedicines12061331 (romano2024recentinsightsinto pages 2-4) | Indicator of severe microvascular disease | | Mechanistic sequence | Triggers → Vasospasm → Ischemia–Reperfusion → EC damage → Maladaptive repair/ulceration | Summarizes progression from cold/emotional triggers to clinical tissue injury via SMC constriction, ROS, endothelial dysfunction and failed angiogenesis | Vascular Specialist International, 2024, https://doi.org/10.5758/vsi.240047 (ture2024raynaud’sphenomenona pages 1-2) | Framework for primary vs SSc-associated disease progression |
Table: Structured knowledge-base table summarizing molecular players, processes, cell types, sites, biomarkers and therapies in Raynaud disease, with linked recent evidence (reviews and mechanistic sources) useful for annotation and curation (ture2024raynaud’sphenomenona pages 1-2, fardoun2025coldresponsesand pages 12-13).
Limitations Some mechanistic facets, such as specific risk loci from recent GWAS and the magnitude of effect of individual variants, require direct citation of those primary genetics papers; the above integrates 2023–2024 reviews and mechanistic syntheses with selective 2025 updates where they clarify pathways relevant to 2023–2024 practice. (ture2024raynaud’sphenomenona pages 1-2, romano2024recentinsightsinto pages 2-4, patnaik2023endothelialdysfunctionin pages 7-8)
References
(ture2024raynaud’sphenomenona pages 1-2): Hirut Yadeta Ture, Nan Young Lee, Na Ri Kim, and Eon Jeong Nam. Raynaud’s phenomenon: a current update on pathogenesis, diagnostic workup, and treatment. Vascular Specialist International, Jul 2024. URL: https://doi.org/10.5758/vsi.240047, doi:10.5758/vsi.240047. This article has 31 citations.
(romano2024recentinsightsinto pages 2-4): Eloisa Romano, Irene Rosa, Bianca Saveria Fioretto, and Mirko Manetti. Recent insights into cellular and molecular mechanisms of defective angiogenesis in systemic sclerosis. Biomedicines, 12:1331, Jun 2024. URL: https://doi.org/10.3390/biomedicines12061331, doi:10.3390/biomedicines12061331. This article has 17 citations and is from a poor quality or predatory journal.
(patnaik2023endothelialdysfunctionin pages 7-8): Eshaan Patnaik, Matthew Lyons, Kimberly Tran, and Debendra Pattanaik. Endothelial dysfunction in systemic sclerosis. International Journal of Molecular Sciences, 24:14385, Sep 2023. URL: https://doi.org/10.3390/ijms241814385, doi:10.3390/ijms241814385. This article has 52 citations and is from a poor quality or predatory journal.
(fardoun2025coldresponsesand pages 10-11): Manal Fardoun, Odette El Ghawi, Christie Dib, Leen Jaradi, Marie Therese Chaddad, Hassan Dehaini, and Ali H. Eid. Cold responses and hormonal echoes: a comprehensive view of raynaud’s vascular dysfunction. Inflammopharmacology, 33:3637-3651, Jun 2025. URL: https://doi.org/10.1007/s10787-025-01792-0, doi:10.1007/s10787-025-01792-0. This article has 2 citations and is from a peer-reviewed journal.
(oztan2024determinationofmolecular pages 7-8): Gözde Öztan. Determination of molecular pathways and gene ontology of genes associated with raynaud’s phenomenon. Turkish Journal of Biochemistry, 49:560-567, Jun 2024. URL: https://doi.org/10.1515/tjb-2023-0197, doi:10.1515/tjb-2023-0197. This article has 0 citations.
(ture2024raynaud’sphenomenona pages 12-14): Hirut Yadeta Ture, Nan Young Lee, Na Ri Kim, and Eon Jeong Nam. Raynaud’s phenomenon: a current update on pathogenesis, diagnostic workup, and treatment. Vascular Specialist International, Jul 2024. URL: https://doi.org/10.5758/vsi.240047, doi:10.5758/vsi.240047. This article has 31 citations.
(fardoun2025coldresponsesand pages 14-15): Manal Fardoun, Odette El Ghawi, Christie Dib, Leen Jaradi, Marie Therese Chaddad, Hassan Dehaini, and Ali H. Eid. Cold responses and hormonal echoes: a comprehensive view of raynaud’s vascular dysfunction. Inflammopharmacology, 33:3637-3651, Jun 2025. URL: https://doi.org/10.1007/s10787-025-01792-0, doi:10.1007/s10787-025-01792-0. This article has 2 citations and is from a peer-reviewed journal.
(fardoun2025coldresponsesand pages 12-13): Manal Fardoun, Odette El Ghawi, Christie Dib, Leen Jaradi, Marie Therese Chaddad, Hassan Dehaini, and Ali H. Eid. Cold responses and hormonal echoes: a comprehensive view of raynaud’s vascular dysfunction. Inflammopharmacology, 33:3637-3651, Jun 2025. URL: https://doi.org/10.1007/s10787-025-01792-0, doi:10.1007/s10787-025-01792-0. This article has 2 citations and is from a peer-reviewed journal.